However, not all companion diagnostic tests are clinically useful; clinical benefit of cetuximab treatment in metastatic colorectal carcinoma was not related to EGFR immunostaining results [26], and trastuzumab response rate in HER2-positive GC remains less than 50% [11]. This evidence concerns the gene ERBB2 and gastric cancer.